PT-141
Also known as Bremelanotide · Vyleesi
A melanocortin-receptor agonist used for sexual-function support — FDA-approved as Vyleesi for acquired hypoactive sexual desire disorder in women.
Definition
A synthetic peptide that activates the melanocortin-4 receptor in the central nervous system, increasing sexual arousal through a pathway independent of vascular mechanisms like sildenafil.
How Meto uses it.
Meto prescribes compounded PT-141 following hormone lab review and cardiovascular assessment. Dosing is subcutaneous, 0.75-1.75 mg, 30-60 minutes before desired effect; it's PRN rather than daily.
Safety notes
- Contraindicated in uncontrolled hypertension and cardiovascular disease
- Transient blood pressure rise of ~5-10 mmHg within 4-6 hours
- Facial flushing and mild nausea are common at effective doses
- Avoid in pregnancy and lactation
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
How is PT-141 different from sildenafil?
Sildenafil (Viagra) is a vascular drug — it increases blood flow. PT-141 is a central-nervous-system drug.
Does it work for women?
Yes — FDA-approved specifically for premenopausal women with HSDD (as Vyleesi).
Read More
Oxytocin
A naturally occurring nine-amino-acid peptide hormone that governs social bonding, childbirth and lactation — used clinically in specific compounded contexts.
Pharmacy & RegulationCompounded Peptide
A peptide prepared for an individual patient by a licensed compounding pharmacy, prescribed by a clinician and tested for identity, potency and contamination.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.